• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $HYFT

    MindWalk Holdings Corp.

    Subscribe to $HYFT
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for MindWalk Holdings Corp.

    DatePrice TargetRatingAnalyst
    See more ratings

    MindWalk Holdings Corp. SEC Filings

    View All

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    10/21/25 4:01:02 PM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    10/21/25 9:42:41 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    10/15/25 9:50:13 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    10/10/25 6:01:03 PM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    10/9/25 9:36:53 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    9/22/25 9:51:05 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    9/15/25 8:51:48 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    9/15/25 8:51:11 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    9/10/25 9:41:57 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp. Press Releases

    Fastest customizable press release news feed in the world

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. "Tom's combination of biotech depth and software commercialization expertise directly supports MindWalk's next path of growth," said Dr. Jennifer Bath CEO of MindWalk. "As we expand the reach of our HYFT-powered Deep Data platform across pharma and biotech markets worldwide, Tom's leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value." Dr. Lynch is an accomplished industry lead

    10/15/25 7:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Announces Share Repurchase Program

    MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ: "HYFT"), a bio-native AI company, today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the "Board") has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the Company, no par value (the "Common Shares") over the twelve-month period commencing on October 15th, 2025, and ending no later than October 15th, 2026 (the "Program"). This represents approximately 5% of the 46,154,188 Common Shares currently issued and outstanding. CEO Jennifer Bath stated, "With our balance sheet significantly strengthen

    10/9/25 7:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

    Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging biology -- targeting the widely projected $60B longevity therapeutics market HYFT®-driven discovery supports co-administration of MindWalk's proprietary companion therapeutic with the Company's GLP-1 receptor agonist MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company, today announced a major advancement of its AI-designed GLP-1 therapeutics program. New insights from the Company's LensAI™ platform reveal a previously unrecognized connection between GLP-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. The

    9/22/25 7:02:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

    Company to hold conference call on September 15, 2025, at 10:30 ET to review corporate highlights MindWalk Holdings Corp.™ ("MindWalk™", "Company", "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. First Quarter Highlights: Record revenue of $7.6 million, up 45% year-over-year; continued operations revenue of $3.2 million, up 28% Gross margin expanded to 53%; gross profit $4.0 million vs. $2.4 million last year Operating loss and adjusted

    9/15/25 8:44:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025

    The Company to host an earnings conference call via webcast MindWalk (NASDAQ:HYFT) ("HYFT" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year end 2026, on Monday, September 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss

    9/10/25 8:16:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp. Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. "Tom's combination of biotech depth and software commercialization expertise directly supports MindWalk's next path of growth," said Dr. Jennifer Bath CEO of MindWalk. "As we expand the reach of our HYFT-powered Deep Data platform across pharma and biotech markets worldwide, Tom's leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value." Dr. Lynch is an accomplished industry lead

    10/15/25 7:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp. Financials

    Live finance-specific insights

    View All

    MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

    Company to hold conference call on September 15, 2025, at 10:30 ET to review corporate highlights MindWalk Holdings Corp.™ ("MindWalk™", "Company", "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. First Quarter Highlights: Record revenue of $7.6 million, up 45% year-over-year; continued operations revenue of $3.2 million, up 28% Gross margin expanded to 53%; gross profit $4.0 million vs. $2.4 million last year Operating loss and adjusted

    9/15/25 8:44:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025

    The Company to host an earnings conference call via webcast MindWalk (NASDAQ:HYFT) ("HYFT" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year end 2026, on Monday, September 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss

    9/10/25 8:16:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care